Background: Oxidative stress mitigated by antioxidant enzymes is thought to be involved in the progression to castrationresistant prostate cancer (CRPC) during androgen-deprivation therapy (ADT). This study investigated the association between genetic variations in antioxidant enzymes and the efficacy of ADT as well as its biological background.
Introduction
Androgen-deprivation therapy (ADT) is the gold-standard therapy for recurrent or advanced prostate cancer [1] . However, most eventually recur in a castration-resistant fashion during ADT, defined as castration-resistant prostate cancer (CRPC), for which several novel agents including antiandrogen enzalutamide have been developed and which have improved the prognosis of CRPC patients [1] . Oxidative stress has a key role in prostate carcinogenesis as well as prostate cancer progression [2] [3] [4] . So far, several groups have reported that oxidative stress and its related factors can modulate androgen receptor (AR) transcriptional activity [4] [5] [6] , which leads to the development of CRPC. In addition to AR signaling, non-AR signaling modulated by oxidative stress can promote the progression to CRPC [7] . Thus, oxidative stress has recently been suggested to convert androgen-dependent prostate cancer into CRPC through various mechanisms [8] .
Several genetic polymorphisms have been reported to be involved in the efficacy of ADT and prognosis of prostate cancer treated with ADT, which include androgen-signaling related genes that encode androgen-metabolic enzymes, such as CYP19A1, HSD3B1, HSD17B4, CYP17A1 and SRD5A2 [9] [10] [11] , androgen transporter SLCO1B3 [12, 13] and SLCO2B1 [14] , and AR splicing regulator YB-1 [15] as well as growth-hormone signaling, such as insulin-like growth factor-1 (IGF-1) [16] and epidermal growth factor (EGF) [17] .
Various antioxidant enzymes including superoxide dismutases (SODs), catalase (CAT), and glutathione S-transferases (GSTs) ameliorate oxidative stress by detoxifying reactive oxygen species (ROS) such as superoxide, hydrogen peroxide and hydrogen radical. Those antioxidant enzymes are involved in modulating oxidative stress status induced by various stimuli, implicating genetic variations may affect the progression to CRPC through oxidative stress. However, an association between genetic polymorphisms in antioxidant enzymes and the efficacy of ADT has not been reported. Therefore, we investigated the impact of genetic polymorphisms in SODs, CAT and GSTs on the efficacy of ADT in Japanese men with prostate cancer as well as elucidating its biological background.
Methods Patients
Patients with metastatic prostate cancer to regional lymph node and/or distant sites were employed as discovery set, which cohort was utilized in our previous studies [11, 15] . As validation set, patients with non-metastatic prostate cancer treated with primary ADT or salvage ADT for prostatespecific antigen (PSA) recurrence after definitive therapy with radical prostatectomy or radiotherapy for prostate were employed. All patients were histopathologically diagnosed with adenocarcinoma of the prostate. Clinical staging was determined according to the unified TNM criteria based on the results of a digital rectal examination, transrectal ultrasound, computed tomography, magnetic resonance imaging, and bone scan [18] . ADT was initiated from 1993 to 2014, and conducted with surgical or medical castration using a luteinizing hormone-releasing hormone agonist (goserelin acetate or leuprorelin acetate) and/or an antiandrogen agent (bicalutamide, flutamide, or chlormadinone acetate). The oncological outcome was defined as described previously [14] . Briefly, time to progression was defined as the duration from ADT initiation to the date of progression to CRPC. CRPC was defined according to three consecutive increments in PSA resulting in two 50% increases over the nadir despite consecutive ADT, or progression or appearance of two lesions on a bone scan and soft tissue lesions. For most patients, antiandrogen withdrawal, antiandrogen switch, estradiol agents (fosfestrol, ethinylestradiol and estramustine), and steroidal agents (dexamethasone and prednisolone) were sequentially utilized at progression to CRPC. Overall survival was calculated from the ADT initiation to death or the last follow-up day.
Blood samples were obtained from patients with prostate cancer that had undergone ADT from 1993 to 2005 when initially diagnosed as prostate cancer at Kyushu University and University of Occupational and Environmental Health. Written informed consent was obtained from all patients. This study was performed in accordance with the principles described in the Declaration of Helsinki and the Ethical Guidelines for Epidemiological Research enacted by the Japanese Government, and approved by each institutional review board.
SNP selection
Among various SNPs in SODs, CAT, and GSTs genes, SNPs with over 5% frequency causing a missense mutation in the coding region or affecting gene expression in a promoter region were selected for investigation.
, and rs156697 (N114D) in GSTO2 were investigated in this study.
Polymorphism genotyping, measurement of serum testosterone level, cell lines, flow cytometric ROS determinations, RNA isolation, reverse transcription, and quantitative real-time polymerase chain reaction (PCR)
Those methods were described in Supplementary Materials.
Statistical analysis
Statistical analyses were performed using JMP11 software (SAS Institute, Cary, NC). Comparisons between groups were analysed by Student's ttest, Wilcoxon rank sum test or Fisher's exact tests. Survival analyses were conducted using the Kaplan-Meier method and the log-rank test. Cox proportional hazards model was used to estimate hazard ratios (HRs) while the Bonferroni adjustment was employed for multiple comparisons. All P values are two-sided. Levels of statistical significance were set at P < 0.05.
Results

Prognostic significance of antioxidant enzymes SNPs in discovery set
Patients' characteristics with metastatic prostate cancer were shown in supplementary Table S1 , available at Annals of Oncology online. Most patients in this study showed high PSA levels with a median of 244.0 ng/ml, high Gleason score over 7 and advanced stages (T3 and T4) with regional lymph node and/or distant metastasis. During the median follow-up duration of 3.7 years (interquartile range; IQR, 1.6-7.6), 80 cases (76.9%) progressed to CRPC and 60 cases (57.7%) died. Among nine genetic polymorphisms investigated in this study (Table 1) Table 1 ). Thus, genetic polymorphisms in GSTM3 rs7483 and CAT rs564250 were associated with progression and death risks, respectively. However, there was no difference in the clinicopathological background between gene polymorphisms (supplementary Table  S1 , available at Annals of Oncology online). Accordingly, on multivariate analysis using GSTM3 rs7483 and various clinicopathological parameters, only polymorphisms in GSTM3 rs7483 were significantly associated with progression risk (AG/GG versus AA; HR [95% CI], 0.45 [0.25-0.79], P ¼ 0.0047) even after Bonferroni adjustment, while no clinicopathological parameter was a significant progression risk, probably because of the small sample size used in this study (Table 2) . However, on multivariate analysis using CAT rs564250 and various clinicopathological parameters, a polymorphism in CAT rs564250 was marginally associated with all-cause death risk (CT/TT versus CC; HR [95% CI], 0.53 [0.24-1.07], P ¼ 0.078) while age and clinical T-stage were significantly correlated with death risk (Table 2 ).
Prognostic significance of GSTM3 polymorphism in validation set
To confirm that genetic polymorphism in GSTM3 rs7483 is a biomarker for the efficacy of ADT, we performed validation study using distinct cohort including patients with non-metastatic prostate cancer. Patients' characteristics were shown in supplementary Table S2 , available at Annals of Oncology online. Most patients in this study showed lower PSA levels with a median of 12.7 ng/ml, low Gleason score <8 and localized stages (T1 and T2). During the median follow-up duration of 6.5 years (IQR, 3.3-9. The duration of progression-free survival (P ¼ 0.044) and overall survival (P ¼ 0.060) among men with the AG/GG allele in GSTM3 rs7483 were significantly and marginally longer compared with the AA allele, respectively ( Figure 1C ).
Biological background
To explore whether those genetic variations affected the efficacy of ADT through modulating serum testosterone, we investigated the association between genetic variations in antioxidant enzymes and testosterone levels in 80 cases with metastatic prostate cancer whose testosterone levels during ADT were available [19] . However, there was no correlation between genetic polymorphisms and testosterone levels during ADT (data not shown).
To investigate further the potential mechanism involved in how gene polymorphisms in antioxidant enzymes affect the efficacy of ADT, we examined intracellular ROS levels and gene expression levels of the various antioxidant enzymes listed in Supplementary Materials in castration-resistant and enzalutamide-resistant prostate cancer cells. As shown in Figure  2A , intracellular ROS levels were increased in castration-resistant CxR cells compared with parental LNCaP cells as well as in enzalutamide-resistant 22Rv1/MDV cells compared with parental 22Rv1 cells. Concurrently, GSTM3 expression increased in both castration-resistant CxR and enzalutamide-resistant 22Rv1/ MDV cells ( Figure 2B ). In addition, most antioxidant enzymes including CAT were up-regulated in enzalutamide-resistant 22Rv1/MDV cells while castration-resistant CxR cells showed a varied expression of antioxidant enzymes (Figures 2B and supplementary Figure S1 , available at Annals of Oncology online).
Discussion
To the best of our knowledge, this study is the first report to examine the effect of polymorphisms in antioxidant enzymes on the efficacy of ADT, showing that the non-synonymous GSTM3 rs7483 polymorphism robustly correlated with a risk of progression in men with prostate cancer treated with ADT. Thus, this study suggested that genetic polymorphism in GSTM3 rs7483 might be a promising biomarker to predict the outcome of ADT in prostate cancer because SNP analysis is feasible for clinical use compared with other emerging technologies such as liquid biopsy. Therefore, incorporation of GSTM3 rs7483 into the established prognostic model such as Glass classification [20] and J-CAPRA model [21] might help improve diagnostic accuracy, although further validation study would be warranted. The GSTM3 AA genotype has been reported to increase the risk of Alzheimer disease susceptibility, and was correlated with the decreased expression of GSTM3, suggesting lower antioxidant ability in the AA genotype of GSTM3 [22] . However, an enzymatic activity study indicated the increased activity of AA genotype of GSTM3 [23] . Taken together, although these results suggest the antioxidant role of the polymorphism in GSTM3 rs7483 is controversial, the differential enzymatic activity between genetic polymorphisms might contribute to the efficacy of ADT through defensive activity to oxidative stress. However, it remains obscure how detoxifying activity to oxidative stress influences the efficacy of ADT. To delineate this interaction, we investigated intracellular ROS levels as well as gene expression levels of antioxidant enzymes in castration-and enzalutamide-resistant prostate cancer. Previously, we reported that androgen depletion induced oxidative stress [5] . In addition, the current study showed oxidative stress levels were elevated in castration-and enzalutamide-resistant cells. Several previous studies reported that antioxidant enzymes including GSTP1 [24, 25] , GPX2 [26] , and Prdxs [27] as well as various antioxidant enzymes including GSTM3 were up-regulated in CRPC, suggesting a higher level of oxidative stress in resistant cells induces the expression of antioxidant enzymes. Intriguingly, several antioxidant enzymes such as Prdxs have been reported to play a role promoting AR signaling, leading to the progression to CRPC [27, 28] . Therefore, this finding supports the hypothesis that oxidative stress promotes castration-resistant progression. Based on this hypothesis, enzymes encoded by the GSTM3 AA genotype related to a poor outcome might be connected with a lower antioxidant activity leading to higher ROS levels, or the effect of GSTM3 on augmenting AR activity because GSTs were reported to be enzymes and transporters of steroids [29, 30] , which should be clarified in the future.
Because this study included several limitations such as a relatively small sample size, long period of accrual, and being a retrospective study including only cases from the Japanese population, a validation study is required using a prospectively collected larger sample size and/or other ethnic groups. There was no significant association between polymorphisms in GSTM3 and overall survival in discovery cohort, which may be affected by subsequent therapy after ADT. This study could not determine oxidative stress levels in cases, and therefore was unable to provide proof of concept that the activity of antioxidant enzymes affects the efficiency of ADT, thus warranting further study.
In conclusion, the GSTM3 rs7483 polymorphism was associated with recurrence and prognosis in patients with prostate cancer who underwent ADT, maybe by altering oxidative stress status. Therefore, the GSTM3 rs7483 polymorphism might be a novel biomarker to predict the efficacy of ADT. Furthermore, these findings might suggest the involvement of antioxidant enzymes in the biology of progression to CRPC. However, further study using larger cohort and the investigation on the association between oxidative stress and CRPC would be required in the future.
